SUMM Summit Therapeutics Plc

Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its financial results for the third quarter and nine months ended 31 October 2016 on Thursday, 15 December 2016.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease DMD and the infectious disease Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics Glyn Edwards / Richard Pye (UK office)Erik Ostrowski / Michelle Avery (US office)	Tel: +44 (0)1235 443 951       +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser)Liam Murray / Tony Rawlinson	Tel: +44 (0)20 7213 0880
N+1 Singer (Broker)Aubrey Powell / Jen Boorer	Tel: +44 (0)20 7496 3000
MacDougall Biomedical Communications(US media contact)Chris Erdman / Karen Sharma	Tel: +1 781 235 3060 cerdman@macbiocom.com / ksharma@macbiocom.com
Consilium Strategic Communications (Financial public relations, UK)Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville	Tel: +44 (0)20 3709 5700summit@consilium-comms.com